PhotoMedex to Hold First Quarter 2009 Conference Call
2009-05-07 20:46:03 -
PhotoMedex, Inc. (Nasdaq: PHMD : cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Ffin .. ) will hold a conference call to discuss the Company's first quarter 2009 results on Thursday, May 14, 2009 at 4:30 p.m. Eastern Time.
The first quarter results will be announced on May 14th, prior to the conference call.
To participate in the conference call, dial 800-432-7890 (and confirmation code # 3790427) approximately 5 to 10
minutes prior to the scheduled start time. If you are unable to participate, a digital replay of the call will be available from Thursday, May 14, from 7:30 p.m. ET until midnight on Thursday, May 28, 2009 by dialing 888-203-1112 and using confirmation code # 3790427.
The live broadcast of PhotoMedex, Inc.'s quarterly conference call will be available online by going to www.photomedex.com :
cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww .. and clicking on the link to Investor Relations, and at www.streetevents.com :
cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww .. .
The online replay will be available shortly after the call at those sites.
About PhotoMedex:
PhotoMedex offers a wide range of products and services across multiple specialty areas, including dermatology, urology, gynecology, orthopedics and other surgical specialties. PhotoMedex is a leader in the development, manufacturing and marketing of medical laser products and services. PhotoMedex also develops and markets products based on its patented, clinically proven Copper Peptide technology for skin health, hair care and wound care. PhotoMedex sells directly to dermatologists, plastic and cosmetic surgeons, spas and salons and through licenses with strategic partners into the consumer market, including a long-term worldwide license agreement with Neutrogena(R), a Johnson & Johnson company. ProCyte brands include Neova(R), Ti-Silc(R), VitalCopper(R), Simple Solutions(R) and AquaSante(R).
In addition, as a result of the recent merger with Photo Therapeutics, PhotoMedex now researches, develops and manufactures non-laser light devices for the treatment of clinical and aesthetic dermatological conditions and adds the Omnilux(tm) products to its arsenal. The Omnilux(tm) products incorporate a new technology based on narrowband Light Emitting Diodes (LEDs) to treat a wide range of dermatological conditions including acne, photodamage, skin rejuvenation, psoriasis, post-surgery wound healing and non-melanoma skin cancer.
Safe Harbor Statement
Some portions of the conference call, particularly those describing PhotoMedex' strategies, operating expense reductions and business plans, will contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. While PhotoMedex is working to achieve those goals, actual results could differ materially from those projected in the forward-looking statements as a result of a number of factors, including difficulties in marketing its products and services, need for capital, competition from other companies and other factors, any of which could have an adverse effect on the business plans of PhotoMedex, its reputation in the industry or its results. In light of significant uncertainties inherent in forward-looking statements included herein and in the conference call, the inclusion of such information in the conference call should not be regarded as a representation by PhotoMedex or its subsidiaries that the forward looking statements will be achieved.
PhotoMedex, Inc.Dennis McGrath, CFO, 215-619-3287
info@photomedex.com : mailto:info@photomedex.com orInvestor
Contacts:Lippert/Heilshorn & Associates, Inc.Kim
Sutton Golodetz, 212-838-3777
Kgolodetz@lhai.com : mailto:Kgolodetz@lhai.com orBruce
Voss, 310-691-7100
Bvoss@lhai.com : mailto:Bvoss@lhai.com
